Landos Biopharma: Lanthionine Synthetase C-Like 2 (LANCL2) is a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Successfully raised $60MM Series B in August 2019 with Perceptive and RTW.